Close

Baxter Int't (BAX) Reports BAX 111 Met Primary Efficacy Endpoint in PK Phase 3

April 16, 2014 9:00 AM EDT Send to a Friend
Baxter International, Inc. (NYSE: BAX) announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login